These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 15739619)
21. Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS). Kesel AJ Curr Med Chem; 2005; 12(18):2095-162. PubMed ID: 16101496 [TBL] [Abstract][Full Text] [Related]
22. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. Pfefferle S; Schöpf J; Kögl M; Friedel CC; Müller MA; Carbajo-Lozoya J; Stellberger T; von Dall'Armi E; Herzog P; Kallies S; Niemeyer D; Ditt V; Kuri T; Züst R; Pumpor K; Hilgenfeld R; Schwarz F; Zimmer R; Steffen I; Weber F; Thiel V; Herrler G; Thiel HJ; Schwegmann-Wessels C; Pöhlmann S; Haas J; Drosten C; von Brunn A PLoS Pathog; 2011 Oct; 7(10):e1002331. PubMed ID: 22046132 [TBL] [Abstract][Full Text] [Related]
23. Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. Li Q; Zhao Z; Zhou D; Chen Y; Hong W; Cao L; Yang J; Zhang Y; Shi W; Cao Z; Wu Y; Yan H; Li W Peptides; 2011 Jul; 32(7):1518-25. PubMed ID: 21620914 [TBL] [Abstract][Full Text] [Related]
25. Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. Kumaki Y; Day CW; Wandersee MK; Schow BP; Madsen JS; Grant D; Roth JP; Smee DF; Blatt LM; Barnard DL Biochem Biophys Res Commun; 2008 Jun; 371(1):110-3. PubMed ID: 18406349 [TBL] [Abstract][Full Text] [Related]
26. Development of antiviral therapy for severe acute respiratory syndrome. Cinatl J; Michaelis M; Hoever G; Preiser W; Doerr HW Antiviral Res; 2005 Jun; 66(2-3):81-97. PubMed ID: 15878786 [TBL] [Abstract][Full Text] [Related]
27. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future]. Ye ZW; Jin DY Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053 [TBL] [Abstract][Full Text] [Related]
28. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. ter Meulen J; van den Brink EN; Poon LL; Marissen WE; Leung CS; Cox F; Cheung CY; Bakker AQ; Bogaards JA; van Deventer E; Preiser W; Doerr HW; Chow VT; de Kruif J; Peiris JS; Goudsmit J PLoS Med; 2006 Jul; 3(7):e237. PubMed ID: 16796401 [TBL] [Abstract][Full Text] [Related]
29. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2. Zheng Z; Monteil VM; Maurer-Stroh S; Yew CW; Leong C; Mohd-Ismail NK; Cheyyatraivendran Arularasu S; Chow VTK; Lin RTP; Mirazimi A; Hong W; Tan YJ Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700671 [TBL] [Abstract][Full Text] [Related]
30. Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS. Zhang MY; Choudhry V; Xiao X; Dimitrov DS Curr Opin Mol Ther; 2005 Apr; 7(2):151-6. PubMed ID: 15844623 [TBL] [Abstract][Full Text] [Related]
31. Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid. He R; Adonov A; Traykova-Adonova M; Cao J; Cutts T; Grudesky E; Deschambaul Y; Berry J; Drebot M; Li X Biochem Biophys Res Commun; 2004 Aug; 320(4):1199-203. PubMed ID: 15249217 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Barnard DL; Day CW; Bailey K; Heiner M; Montgomery R; Lauridsen L; Chan PK; Sidwell RW Antivir Chem Chemother; 2006; 17(5):275-84. PubMed ID: 17176632 [TBL] [Abstract][Full Text] [Related]
33. Treatment and vaccines for severe acute respiratory syndrome. Groneberg DA; Poutanen SM; Low DE; Lode H; Welte T; Zabel P Lancet Infect Dis; 2005 Mar; 5(3):147-55. PubMed ID: 15766649 [TBL] [Abstract][Full Text] [Related]
34. Potential antivirals and antiviral strategies against SARS coronavirus infections. De Clercq E Expert Rev Anti Infect Ther; 2006 Apr; 4(2):291-302. PubMed ID: 16597209 [TBL] [Abstract][Full Text] [Related]
35. Recent developments in the virology and antiviral research of severe acute respiratory syndrome coronavirus. Yeung KS; Meanwell NA Infect Disord Drug Targets; 2007 Mar; 7(1):29-41. PubMed ID: 17346209 [TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus. Lip KM; Shen S; Yang X; Keng CT; Zhang A; Oh HL; Li ZH; Hwang LA; Chou CF; Fielding BC; Tan TH; Mayrhofer J; Falkner FG; Fu J; Lim SG; Hong W; Tan YJ J Virol; 2006 Jan; 80(2):941-50. PubMed ID: 16378996 [TBL] [Abstract][Full Text] [Related]
37. High-throughput assay using a GFP-expressing replicon for SARS-CoV drug discovery. Ge F; Xiong S; Lin FS; Zhang ZP; Zhang XE Antiviral Res; 2008 Nov; 80(2):107-13. PubMed ID: 18584889 [TBL] [Abstract][Full Text] [Related]
38. Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level. Stadler K; Ha HR; Ciminale V; Spirli C; Saletti G; Schiavon M; Bruttomesso D; Bigler L; Follath F; Pettenazzo A; Baritussio A Am J Respir Cell Mol Biol; 2008 Aug; 39(2):142-9. PubMed ID: 18314540 [TBL] [Abstract][Full Text] [Related]
39. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Zhu Z; Chakraborti S; He Y; Roberts A; Sheahan T; Xiao X; Hensley LE; Prabakaran P; Rockx B; Sidorov IA; Corti D; Vogel L; Feng Y; Kim JO; Wang LF; Baric R; Lanzavecchia A; Curtis KM; Nabel GJ; Subbarao K; Jiang S; Dimitrov DS Proc Natl Acad Sci U S A; 2007 Jul; 104(29):12123-8. PubMed ID: 17620608 [TBL] [Abstract][Full Text] [Related]